Lumipulse® G CA125-II
Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of CA125 in serum or plasma.
The assay utilises proven CLEIA (ChemiLuminescent Enzyme Immunoassay) technology with results that are available in up to 35 minutes.
Product number 292631
Click here to navigate
- Conditions of sale
- Related products
- Product inquiry
See the LUMIPULSE G1200 working in this video:
Conditions of sale
To read the end user conditions of sale for this product please visit our Resource center.
The American Cancer Society has estimated that in 2021, about 21,410 women in the US will receive a new diagnosis of ovarian cancer (OC), and about 13...
Aug 23, 2021
Over the last decades, biomarkers have become an extremely important tool in the care of patients with ovarian cancer. Biomarkers are capable of...
Mar 1, 2021
It has been estimated that in 2020, about 21,750 women in the US will receive a new ovarian cancer diagnosis and about 13,940 women will die from this...
Jul 29, 2020
How does the coronavirus disease Covid-19 impact Fujirebio's operations?
Please see the following statement on the impact of coronavirus disease Covid-19 on the operations of Fujirebio Europe (updated January 19, 2021).
Tumor Marker Control
Product number 108-20W -
Tumor Marker Control is intended for use as an assayed control serum to monitor the precision of laboratory testing procedures for the analytes listed in the lot specific assigned values sheet.CE marked
Lumipulse® G HE4 (Human epididymis protein 4)
Product number 234068 -
Immunoreaction cartridges for in vitro diagnostics (IVD) use with the LUMIPULSE G System for the quantitative measurement of HE4 in human serum or plasma (sodium haparin, lithium heparin, or dipotassium EDTA) on the LUMIPULSE G System.CE marked
CanAg® CA125 EIA
Product number 400-10 -
The CanAg CA125 EIA kit is intended for the quantitative determination of the cancer associated antigen CA125 in serum.CE marked
Product number 404-10 -
The HE4 EIA is an enzyme immunometric assay for the quantitative determination of HE4 in human serum. The assay is to be used as an aid in monitoring response to therapy for patients with invasive epithelial ovarian cancer. Serial testing for patient HE4 assay values should be used in conjunction with other clinical methods used for monitoring ovarian cancer. It is further intended to be used in conjunction with either ARCHITECT CA 125 II or CanAg CA125 EIA or Lumipulse G CA125II as an aid in estimating the risk of epithelial ovarian cancer in premenopausal and postmenopausal women presenting with pelvic mass. The results must be interpreted in conjunction with other methods in accordance with standard clinical management guidelines.CE marked
Product number 203-01R, 212-01R, 406-01, 407-01R, 408-01, 201-850, 205-485 -
The CA125 monoclonal antibodies recognize epitopes in the protein core of the CA125 antigen.
Product number 703380 -
The LUMIPULSE G600II is the latest member of the Lumipulse G series of chemiluminescent enzyme immunoassay analyzers (CLEIA) from Fujirebio.CE marked